Status: Recruiting
Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.
A non randomized observation study that is aiming to assess the safety and efficacy of high dose primaquine (1mg/kg per day over 7 days) among patients with intermediate (30-70%) G6PD activity and the safety and efficacy of weekly primaquine among patients who are g6Pd deficient (\<30% activity)
Participants needed: 100
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Menzies School of Health ResearchUpdated: Mar 12, 2026Locations: 4
Eligibility criteria
• P. vivax peripheral parasitaemia (mono-infection) [+6]
• Danger signs or symptoms of severe malaria [+3]